bevacizumab,trifluridine tipiracil
taiho pharma,roche,otsuka
[]
asco #gi23: staggering 3.3 month os benefit of bevacizumab + lonsurf vs lonsurf alone in 3rd line treatment for metastatic colorectal cancer in the randomised sunlight trial. new standard of care for crcs refractory to combination chemo 
Academic GI Cancer Centre in the City of London. Delivering evidence-based treatments and clinical trials to patients. Informing and education patients and HCPs